Company News: Celgene and Abraxis BioScience

Share this article:
New Jersey-based biotech Celgene announced an agreement to purchase Abraxis BioScience, a biotech focused on cancer treatments, for $2.9 billion. Abraxis BioScience markets Abraxane, a chemotherapy treatment option for metastatic breast cancer, which netted $314.5 million in 2009, down from $335.6 in 2008, according to an Abraxis annual report.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.